Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

109.75 -1.01 (-0.91%)
Streaming Delayed Price Updated: 11:11 AM EDT, Sep 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 70,552
Open 111.17
Bid (Size) 109.68 (2)
Ask (Size) 109.83 (1)
Prev. Close 110.76
Today's Range 109.72 - 111.79
52wk Range 99.06 - 137.38
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms
Veterans: Epidiolex shows promise in treating Gulf War Illness, offering hope for those affected. Learn how it might benefit them. 
Via Benzinga
Despite its impressive fundamentals, NASDAQ:JAZZ remains undervalued.
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals. 
Via Chartmill

Performance

YTD
-13.54%
-13.54%
1 Month
-3.62%
-3.62%
3 Month
-0.07%
-0.07%
6 Month
-9.14%
-9.14%
1 Year
-17.17%
-17.17%

More News

Read More
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
When you look at NASDAQ:JAZZ, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Via Benzinga
'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine
Via Benzinga
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals
Via Benzinga
How Is The Market Feeling About Jazz Pharmaceuticals?
Via Benzinga
The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal
Via Benzinga
In a market where value is scarce, NASDAQ:JAZZ offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
The 3 Best Cannabis Stocks to Buy in August 2024
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
3 Biotech Stocks to Buy on the Dip: July 2024
Via InvestorPlace
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
Via Investor's Business Daily
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
Via InvestorPlace
Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts
Via Benzinga
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
Via Benzinga
Topics Cannabis
Exposures Cannabis
Avicanna Exports Cannabinoids To Singapore Legally — Even Though Cannabis Is Punishable By Death In The Country
Via Benzinga
Topics Cannabis
Exposures Cannabis
3 Mid-Cap Growth Rockets Trading at Deep Discounts to Their Potential
Via InvestorPlace
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Via InvestorPlace
3 Cannabis Stocks That Could Make Your Grandchildren Rich
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?
Via Benzinga
Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure
Via Investor's Business Daily
3 Blue-Chip Stocks to Triple Your Wealth by 2026: June Edition
Via InvestorPlace
This Old Dominion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.